Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, Richardson PG, Soiffer RJ, Ho VT. Roeker LE, et al. Among authors: nageshwar p. Biol Blood Marrow Transplant. 2019 Jan;25(1):137-144. doi: 10.1016/j.bbmt.2018.07.039. Epub 2018 Aug 3. Biol Blood Marrow Transplant. 2019. PMID: 30081073 Free article. Clinical Trial.
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P, Ritz J, Nikiforow S, Glotzbecker BE, Nageshwar P, Soiffer RJ, Antin JH, Cutler CS. Gooptu M, et al. Among authors: nageshwar p. Biol Blood Marrow Transplant. 2018 Aug;24(8):1733-1740. doi: 10.1016/j.bbmt.2018.03.011. Epub 2018 Mar 16. Biol Blood Marrow Transplant. 2018. PMID: 29555313 Free article.
Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
Lewis C, Kim HT, Roeker LE, Cutler C, Koreth J, Nikiforow S, Armand P, Gootpu M, Romee R, Glotzbecker B, Nageshwar P, Antin JH, Alyea EP, Richardson P, Soiffer RJ, Ho VT. Lewis C, et al. Among authors: nageshwar p. Biol Blood Marrow Transplant. 2020 Mar;26(3):529-539. doi: 10.1016/j.bbmt.2019.10.024. Epub 2019 Oct 31. Biol Blood Marrow Transplant. 2020. PMID: 31678537 Free article.
Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease.
Kekre N, Kim HT, Hofer J, Ho VT, Koreth J, Armand P, Nikiforow S, Gooptu M, Romee R, Alyea EP, Nageshwar P, Glotzbecker B, El-Jawahri A, DeFilipp Z, Soiffer RJ, Antin JH, Chen YB, Cutler C. Kekre N, et al. Among authors: nageshwar p. Bone Marrow Transplant. 2021 May;56(5):1006-1012. doi: 10.1038/s41409-020-01049-0. Epub 2020 Sep 8. Bone Marrow Transplant. 2021. PMID: 32895491 Clinical Trial.
Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease.
Kekre N, Kim HT, Hofer J, Ho VT, Koreth J, Armand P, Nikiforow S, Gooptu M, Romee R, Alyea EP, Nageshwar P, Glotzbecker B, El-Jawahri A, DeFilipp Z, Soiffer RJ, Antin JH, Chen YB, Cutler C. Kekre N, et al. Among authors: nageshwar p. Bone Marrow Transplant. 2021 May;56(5):1217. doi: 10.1038/s41409-020-01083-y. Bone Marrow Transplant. 2021. PMID: 33041331 No abstract available.